CFM
RVMD icon

Catalyst Funds Management’s Revolution Medicines RVMD Stock Holding History

Catalyst Funds Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-66,261
Closed -$6.44M – 853
2026
Q1 		$6.44M Sell
66,261
-157,308
-70% -$15.9M 1.09% 14
2025
Q4 		$17.8M Buy
223,569
+13,400
+6% +$879K 4.13% 4
2025
Q3 		$9.81M Buy
210,169
+164,569
+361% +$6.44M 1.48% 8
2025
Q2 		$1.68M Buy
+45,600
New +$1.75M 0.46% 57
2024
Q2 		– Sell
-8,400
Closed -$271K – 1536
2024
Q1 		$271K Buy
+8,400
New +$249K 0.08% 209

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Catalyst Funds Management's RVMD Position: Q2 2026 in Review

Catalyst Funds Management sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 66,261 shares — an estimated $6.44M sold.

Catalyst Funds Management first reported a position in RVMD in Q1 2024 and held it in 5 quarters. The position peaked at $17.8M in Q4 2025. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Catalyst Funds Management reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 66,261 Revolution Medicines shares in Q2 2026, an estimated $6.44M.
  • Catalyst Funds Management first reported a position in Revolution Medicines in Q1 2024 and held it in 5 quarters.
  • Catalyst Funds Management's Revolution Medicines position peaked at $17.8M in Q4 2025.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.